Literature DB >> 32419806

The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach.

Xing Lv1, Huijun Wang1,2, Ruoming Wu1, Xiaoyan Shen3, Guan Ye1.   

Abstract

Yixin Ningshen tablet is a CFDA-approved TCM formula for treating coronary heart disease (CHD) clinically. However, its active compounds and mechanism of action in treating CHD are unknown. In this study, a novel strategy with the combination of network pharmacology and proteomics was proposed to identify the active components of Yixin Ningshen tablet and the mechanism by which they treat CHD. With the application of network pharmacology, 62 active compounds in Yixin Ningshen tablet were screened out by text mining, and their 313 potential target proteins were identified by a tool in SwissTargetPrediction. These data were integrated with known CHD-related proteomics results to predict the most possible targets, which reduced the 313 potential target proteins to 218. The STRING database was retrieved to find the enriched pathways and related diseases of these target proteins, which indicated that the Calcium, MAPK, PI3K-Akt, cAMP, Rap1, AGE-RAGE, Relaxin, HIF-1, Prolactin, Sphingolipid, Estrogen, IL-17, Jak-STAT signaling pathway, necroptosis, arachidonic acid metabolism, insulin resistance, endocrine resistance, and steroid hormone biosynthesis might be the main pathways regulated by Yixin Ningshen tablet for the treatment of CHD. Through further enrichment analysis and literature study, EGFR, ERBB2, VGFR2, FGF1, ESR1, LOX15, PGH2, HMDH, ADRB1, and ADRB2 were selected and then validated to be the target proteins of Yixin Ningshen tablet by molecular docking, which indicated that Yixin Ningshen tablet might treat CHD mainly through promoting heart regeneration, new vessels' formation, and the blood supply of the myocardial region and reducing cardiac output, oxygen demand, and inflammation as well as arteriosclerosis (promoting vasodilation and intraplaque neoangiogenesis, lowering blood lipid). This study is expected to benefit the clinical application of Yixin Ningshen tablet for the treatment of CHD.
Copyright © 2020 Xing Lv et al.

Entities:  

Year:  2020        PMID: 32419806      PMCID: PMC7204378          DOI: 10.1155/2020/4912395

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  121 in total

Review 1.  RAGE axis: Animal models and novel insights into the vascular complications of diabetes.

Authors:  Yoshifumi Naka; Loredana G Bucciarelli; Thoralf Wendt; Larisse K Lee; Ling Ling Rong; Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-05-20       Impact factor: 8.311

2.  Modulation of coronary heart disease risk by insulin resistance in subjects with normal glucose tolerance or prediabetes.

Authors:  Danit Ariel; Gerald Reaven
Journal:  Acta Diabetol       Date:  2014-10-31       Impact factor: 4.280

3.  Effect of ginsenoside Rh1 on myocardial injury and heart function in isoproterenol-induced cardiotoxicity in rats.

Authors:  Yusheng Gai; Zhigang Ma; Xiaofeng Yu; Shaochun Qu; Dayuan Sui
Journal:  Toxicol Mech Methods       Date:  2012-07-18       Impact factor: 2.987

4.  β-Sitosterol enhances cellular glutathione redox cycling by reactive oxygen species generated from mitochondrial respiration: protection against oxidant injury in H9c2 cells and rat hearts.

Authors:  Hoi Shan Wong; Na Chen; Pou Kuan Leong; Kam Ming Ko
Journal:  Phytother Res       Date:  2013-11-26       Impact factor: 5.878

Review 5.  Linoleic acid and coronary heart disease.

Authors:  William S Harris
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-10-31       Impact factor: 4.006

6.  Protective effects of ginsenoside Rg2 against H2O2-induced injury and apoptosis in H9c2 cells.

Authors:  Wenwen Fu; Dayun Sui; Xiaofeng Yu; Dongxia Gou; Yifa Zhou; Huali Xu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 7.  Research/review: Insights into the mutation-induced dysfunction of arachidonic acid metabolism from modeling of human CYP2J2.

Authors:  Xiao-Le Xia; Bo-Tao Fa; Shan Cong; Jing-Fang Wang; Kuo-Chen Chou
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

8.  Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model.

Authors:  Seyed Shahabeddin Mortazavi-Jahromi; Shahab Alizadeh; Mohammad Hassan Javanbakht; Abbas Mirshafiey
Journal:  Immunopharmacol Immunotoxicol       Date:  2018-04-05       Impact factor: 2.730

9.  Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content.

Authors:  Susanna Brauner; Xintong Jiang; Gudny Ella Thorlacius; Anna M Lundberg; Therese Östberg; Zhong-Qun Yan; Vijay K Kuchroo; Göran K Hansson; Marie Wahren-Herlenius
Journal:  Cardiovasc Res       Date:  2018-01-01       Impact factor: 10.787

10.  Cardioprotective effects of 5-hydroxymethylfurfural mediated by inhibition of L-type Ca2+ currents.

Authors:  G Wölkart; A Schrammel; C N Koyani; S Scherübel; K Zorn-Pauly; E Malle; B Pelzmann; M Andrä; A Ortner; B Mayer
Journal:  Br J Pharmacol       Date:  2017-09-09       Impact factor: 8.739

View more
  1 in total

1.  Dissecting the mechanism of Yuzhi Zhixue granule on ovulatory dysfunctional uterine bleeding by network pharmacology and molecular docking.

Authors:  Jialin Li; Hua Luo; Xinkui Liu; Jingyuan Zhang; Wei Zhou; Siyu Guo; Xiuping Chen; Yingying Liu; Shanshan Jia; Haojia Wang; Bingbing Li; Guoliang Cheng; Jiarui Wu
Journal:  Chin Med       Date:  2020-10-23       Impact factor: 5.455

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.